Drug firm Lupin today said it has received approval from the UK health regulator for its Goa facility.
The facility was inspected by the United Kingdom's Medicines and Healthcare products Regulatory Agency (UK MHRA) in March 2018 and there were no critical or major observations cited, Lupin said in a filing to BSE.
Commenting on the development, Lupin MD Nilesh Gupta said, "The outcome of this inspection is a positive and encouraging sign for us, and is a testament to our commitment to maintain global manufacturing standards and best practices."
This approval from UK MHRA is a significant development for the company's Goa plant, the filing added.
Shares Of Lupin were today trading at Rs 838.75 per scrip on BSE, down 3.06 per cent from its previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
